---
title: "Roivant CEO Matt Gline said on the conference call that they learned exciting, highly competitively… — Matt Gline — DecisionGateway"
description: "statement by Matt Gline, recorded recently — verbatim quote and source citation."
canonical_url: "https://dgw.tmarket.io/claims/01a1d950-db72-700c-89bd-7101e1154dde"
meta:
  "og:description": "statement by Matt Gline, recorded recently — verbatim quote and source citation."
  "og:image": "https://dgw.tmarket.io/og.jpg"
  "og:image:alt": "White network of connected nodes crossed by a timeline on black"
  "og:image:height": "1024"
  "og:image:width": "1024"
  "og:title": "Roivant CEO Matt Gline said on the conference call that they learned exciting, highly competitively… — Matt Gline — DecisionGateway"
  "twitter:image": "https://dgw.tmarket.io/og.jpg"
---

> Index of every page on this site: [llms.txt](https://dgw.tmarket.io/llms.txt)

statement

# **Roivant CEO Matt Gline said on the conference call that they learned exciting, highly competitively valuable things and will say almost nothing about antibody reduction, but have a good amount of confidence going into phase 3.**

A statement by [**Matt Gline**](https://dgw.tmarket.io/actors/01a1d950-dab5-728a-b91c-ca20d5f29112). Statements are as reported by the cited publishers — not verified by DecisionGateway.

> *경쟁력 측면에서 매우 흥분되고 가치 있는 것들을 알게 되었다. 바로 그러한 이유로 자가항체 감소에 관해서는 어떤 언급도 하지 않겠다. 다만 우리가 배운 것을 바탕으로 임상 3상에 대한 상당한 자신감을 가지고 있다*

hmsecresearchPublished 2026-11-09 [ Read source](https://t.me/hmsecresearch/6167)

[**Matt Gline dossier **](https://dgw.tmarket.io/actors/01a1d950-dab5-728a-b91c-ca20d5f29112)

## **Discussion**

## **More claims by Matt Gline**

No other claims by this actor on record.

[All claims](https://dgw.tmarket.io/claims)

```json
{"@context":"https://schema.org","@graph":[{"@id":"https://dgw.tmarket.io/#website","@type":"WebSite","description":"Decisions, events and falsifiable forecasts from 4,000+ Telegram channels — every claim cited. Read free.","name":"DecisionGateway","url":"https://dgw.tmarket.io/","publisher":{"@id":"https://dgw.tmarket.io/#identity"}},{"@id":"https://dgw.tmarket.io/claims/01a1d950-db72-700c-89bd-7101e1154dde#webpage","@type":"WebPage","description":"statement by Matt Gline, recorded recently — verbatim quote and source citation.","name":"Roivant CEO Matt Gline said on the conference call that they learned exciting, highly competitively… — Matt Gline — DecisionGateway","url":"https://dgw.tmarket.io/claims/01a1d950-db72-700c-89bd-7101e1154dde","breadcrumb":{"@id":"https://dgw.tmarket.io/claims/01a1d950-db72-700c-89bd-7101e1154dde#breadcrumb"},"isPartOf":{"@id":"https://dgw.tmarket.io/#website"},"potentialAction":[{"@type":"ReadAction","target":["https://dgw.tmarket.io/claims/01a1d950-db72-700c-89bd-7101e1154dde"]}]},{"@id":"https://dgw.tmarket.io/#identity","@type":"Organization","name":"DecisionGateway","url":"https://dgw.tmarket.io"},{"@id":"https://dgw.tmarket.io/claims/01a1d950-db72-700c-89bd-7101e1154dde#breadcrumb","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","name":"Home","item":"https://dgw.tmarket.io","position":1},{"@type":"ListItem","name":"Claims","item":"https://dgw.tmarket.io/claims","position":2},{"@type":"ListItem","name":"Roivant CEO Matt Gline said on the conference call that…","position":3}]},{"@id":"https://dgw.tmarket.io/claims/01a1d950-db72-700c-89bd-7101e1154dde#/schema/quotation/1","@type":"Quotation","dateCreated":"2026-11-09","isBasedOn":"https://t.me/hmsecresearch/6167","text":"경쟁력 측면에서 매우 흥분되고 가치 있는 것들을 알게 되었다. 바로 그러한 이유로 자가항체 감소에 관해서는 어떤 언급도 하지 않겠다. 다만 우리가 배운 것을 바탕으로 임상 3상에 대한 상당한 자신감을 가지고 있다","url":"/claims/01a1d950-db72-700c-89bd-7101e1154dde","spokenByCharacter":{"@type":"Person","name":"Matt Gline","@id":"/actors/01a1d950-dab5-728a-b91c-ca20d5f29112"}}]}
```

## Sitemap

See the full [sitemap](https://dgw.tmarket.io/sitemap.md) for all pages.